NLS Pharmaceutics Ltd. Warrant NLSPW 深 沪
已收盘 11-10 16:00:00 美东时间
0.0179
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.0179
- 总市值 6.51万
- 52周最高 0.0698
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.0009
- 委 比 0.00%
- 总股本 363.64万
- 历史最高 2.18
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.0009
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger
Combined Company Re-Named NewcelX Ltd., to Commence Trading on the Nasdaq Capital Market on October 31, 2025 under the Ticker Symbol "NCEL" ZURICH and NESS ZIONA, Israel , Oct. 30, 2025 /PRN...
2025-10-31 04:15
NLS Pharma And Aexon Labs Expand DOXA Platform With AEX-6xx Series, New Generation Of Small Molecules Targeting Arousal Stability, Cognition, And Neuroprotection
DOXA Platform Expansion Strengthens Cognitive, Arousal, and Neuroprotective ProgramsSupported by Solid Cash Position and Strategic Funding OutlookZURICH, Oct. 30, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd.
2025-10-30 19:15
NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs
DOXA Platform Expansion Strengthens Cognitive, Arousal, and Neuroprotective Programs Supported by Solid Cash Position and Strategic Funding Outlook ZURICH, Oct. 30, 2025 /PRNewswire/ -- NLS ...
2025-10-30 19:00
NLS Pharmaceutics, Kadimastem Receive Approval To List Common Shares On Nasdaq After Merger Under NewcelX Name, NCEL Ticker
NLS Pharmaceutics Ltd. (NASDAQ:NLSP) (NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system ("CNS") disorders, and Kadimastem Ltd. (TASE:
2025-10-23 18:04
NLS Pharmaceutics Ltd. Announces Expected Implementation Of 1-For-40 Reverse Share Split
NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and
2024-09-25 20:30
NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering
ZURICH, SWITZERLAND / ACCESSWIRE / March 20, 2024 / NLS Pharmaceutics Ltd. (Nas...
2024-03-21 01:40
NLS Pharmacetics宣布独家期权协议，以开发和商业化Aexon Labs, Inc.的下一代双食欲激动剂平台
The option agreement grants NLS Pharmaceutics Ltd. the exclusive option to in-l...
2023-12-01 08:30
NLS Pharmaceutics Announces Election of Additional Board Members
Professor Claudio L. A. Bassetti, MD, is the Chair, Neurology Department, Insel...
2023-11-28 08:30
NLS Pharmaceutics Company Update and Webcast Today Postponed
NLS to Webcast its Event on Thursday, July 6, 2023, at 11:00 am ET ZURICH, SWIT...
2023-06-30 20:00
NLS Pharmaceutics to Present at the 35th Annual Roth Conference
ZURICH, SWITZERLAND / ACCESSWIRE / March 1, 2023 / NLS Pharmaceutics Ltd. (Nasd...
2023-03-01 21:31
